Logo image of KA

KINETA INC (KA) Stock Fundamental Analysis

NASDAQ:KA - Nasdaq - US49461C1027 - Common Stock - Currency: USD

0.5746  -0.25 (-30.69%)

After market: 0.5995 +0.02 (+4.33%)

Fundamental Rating

0

Overall KA gets a fundamental rating of 0 out of 10. We evaluated KA against 553 industry peers in the Biotechnology industry. KA has a bad profitability rating. Also its financial health evaluation is rather negative. KA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

KA had negative earnings in the past year.
In the past year KA has reported a negative cash flow from operations.
In the past 5 years KA always reported negative net income.
KA had a negative operating cash flow in each of the past 5 years.
KA Yearly Net Income VS EBIT VS OCF VS FCFKA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M

1.2 Ratios

KA has a Return On Assets of -1492.21%. This is amonst the worse of the industry: KA underperforms 99.65% of its industry peers.
Industry RankSector Rank
ROA -1492.21%
ROE N/A
ROIC N/A
ROA(3y)-188.12%
ROA(5y)-135.68%
ROE(3y)-699.02%
ROE(5y)-456.44%
ROIC(3y)N/A
ROIC(5y)N/A
KA Yearly ROA, ROE, ROICKA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -500 -1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for KA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KA Yearly Profit, Operating, Gross MarginsKA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -1K -2K -3K

More info and screens

0

2. Health

2.1 Basic Checks

KA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, KA has more shares outstanding
The number of shares outstanding for KA has been increased compared to 5 years ago.
KA has a worse debt/assets ratio than last year.
KA Yearly Shares OutstandingKA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M
KA Yearly Total Debt VS Total AssetsKA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

KA has an Altman-Z score of -225.92. This is a bad value and indicates that KA is not financially healthy and even has some risk of bankruptcy.
KA has a worse Altman-Z score (-225.92) than 98.59% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -225.92
ROIC/WACCN/A
WACC10.5%
KA Yearly LT Debt VS Equity VS FCFKA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 0.14 indicates that KA may have some problems paying its short term obligations.
KA has a Current ratio of 0.14. This is amonst the worse of the industry: KA underperforms 97.72% of its industry peers.
A Quick Ratio of 0.14 indicates that KA may have some problems paying its short term obligations.
KA has a worse Quick ratio (0.14) than 97.72% of its industry peers.
Industry RankSector Rank
Current Ratio 0.14
Quick Ratio 0.14
KA Yearly Current Assets VS Current LiabilitesKA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

2

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 68.24% over the past year.
Looking at the last year, KA shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
KA shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.89% yearly.
EPS 1Y (TTM)68.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-598.43%
Revenue 1Y (TTM)-100%
Revenue growth 3Y-7.61%
Revenue growth 5Y13.89%
Sales Q2Q%-100%

3.2 Future

KA is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 3.59% yearly.
KA is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -41.42% yearly.
EPS Next Y3.18%
EPS Next 2Y3.59%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
KA Yearly Revenue VS EstimatesKA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M
KA Yearly EPS VS EstimatesKA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2023 2024 2025 -100 -200 -300 -400

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

KA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for KA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KA Price Earnings VS Forward Price EarningsKA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KA Per share dataKA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.5 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.59%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for KA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KINETA INC

NASDAQ:KA (9/18/2024, 8:11:30 PM)

After market: 0.5995 +0.02 (+4.33%)

0.5746

-0.25 (-30.69%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-09 2024-08-09/amc
Earnings (Next)11-01 2024-11-01/amc
Inst Owners0.31%
Inst Owner Change-99.99%
Ins Owners8.53%
Ins Owner Change0%
Market Cap7.04M
Analysts84.44
Price Target13.77 (2296.45%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)0
Avg Revenue beat(4)-100%
Min Revenue beat(4)-100%
Max Revenue beat(4)-100%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.5
EYN/A
EPS(NY)-1.39
Fwd EYN/A
FCF(TTM)-0.78
FCFYN/A
OCF(TTM)-0.78
OCFYN/A
SpS0
BVpS-0.66
TBVpS-0.66
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -1492.21%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-188.12%
ROA(5y)-135.68%
ROE(3y)-699.02%
ROE(5y)-456.44%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.14
Quick Ratio 0.14
Altman-Z -225.92
F-Score2
WACC10.5%
ROIC/WACCN/A
Cap/Depr(3y)40.74%
Cap/Depr(5y)31.08%
Cap/Sales(3y)1.78%
Cap/Sales(5y)1.83%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)68.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-598.43%
EPS Next Y3.18%
EPS Next 2Y3.59%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3Y-7.61%
Revenue growth 5Y13.89%
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y51.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y68.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y68.37%
OCF growth 3YN/A
OCF growth 5YN/A